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Abstract
Background: During the past decade, Taxol has assumed an
important role in cancer chemotherapy. The search for novel
compounds with a mechanism of action similar to that of Taxol,
but with greater efficacy particularly in Taxol-resistant cells,
has led to the isolation of new natural products. One such
compound, (+)-discodermolide, although structurally distinct
from Taxol, has a similar ability to stabilize microtubules. In
addition, (+)-discodermolide is active in Taxol-resistant cell lines
that overexpress P-glycoprotein, the multidrug-resistant transpor-
ter. Interestingly, (+)-discodermolide demonstrates a profound
enhancement of the initiation process of microtubule polymeriza-
tion compared to Taxol.
Results : The synthesis of (+)-discodermolide analogs exploiting
our highly efficient, triply convergent approach has permitted
structure^activity relationship (SAR) studies. Small changes to the
(+)-discodermolide structure resulted in a dramatic decrease in the
ability of all four discodermolide analogs to initiate tubulin
polymerization. Two of the analogs also demonstrated a decrease
in total tubulin polymerization, while a change in the olefin
geometry at the C8 position produced a significant decrease in
cytotoxic activity.
Conclusions: The availability of (+)-discodermolide and the
analogs, and the resultant SAR analysis, have permitted an
exploration of the similarities and differences between (+)-
discodermolide and Taxol. Docking of the X-ray/solution
structure of (+)-discodermolide into the Taxol binding site of L-
tubulin revealed two possible binding modes (models I and II).
The preferred pharmacophore model (I), in which the C19 side
chain of (+)-discodermolide matches with the C2 benzoyl group of
Taxol and the N-lactone ring of (+)-discodermolide overlays with
the C13 side chain of Taxol, concurred with the results of the SAR
analysis. ß 2001 Elsevier Science Ltd. All rights reserved.
Keywords: Discodermolide; Microtubule; Pharmacophore;
Taxol
1. Introduction
Microtubules are required for a host of normal cellular
processes, most importantly mitosis and cell division.
When such an essential structure and the related biological
functions are disrupted, cells can no longer undergo a
normal cell cycle and eventually will die. Microtubules
have become a key target for cancer chemotherapeutic
drugs with many diverse natural compounds targeting
the tubulin/microtubule system. Taxol, isolated from the
Paci¢c Yew tree, has activity against a variety of human
carcinoma cell lines and has been approved for the treat-
ment of human breast, ovarian, and lung carcinomas [1].
In vitro, Taxol induces microtubule assembly in the ab-
sence of GTP that is normally required for assembly [2].
The resultant microtubules are stable against depolymeriz-
ing conditions such as cold temperatures or the addition of
Ca2. Thus, Taxol blocks cells in the mitotic phase of the
cell cycle and causes microtubule bundling, ultimately
leading to cell death [3^5]. Even at low concentrations,
the drug has a major e¡ect on the dynamic instability of
microtubules, reducing the dynamics dramatically [6,7].
Other novel tubulin-stabilizing agents, such as the epo-
thilones, eleutherobin, and (+)-discodermolide, have been
identi¢ed (Fig. 1) [8^11]. These natural products have been
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isolated from a Myxobacterium fermentation, a marine
soft coral, and a marine sponge, respectively. The new
compounds have a mechanism of action very similar to
that of Taxol in that they promote the assembly of stable
microtubules, and induce mitotic arrest and microtubule
bundling in cells, although each with a unique potency. A
number of structure^activity relationship (SAR) and mod-
eling studies have been performed with Taxol, the epothi-
lones, eleutherobin, and (+)-discodermolide in a search for
a common pharmacophore model for these drugs [12^16].
In this report, we provide evidence that (+)-discodermo-
lide ¢ts into a common pharmacophore model.
Although (+)-discodermolide was isolated and originally
identi¢ed as a potential immunosuppressive agent [17],
further studies revealed that the target of (+)-discodermo-
lide was the microtubule system [10,11]. When compared
to Taxol, (+)-discodermolide was found to be more potent
at nucleating tubulin assembly [10,18], at inducing micro-
tubule bundles in MCF-7 cells [10], and to have a higher
a⁄nity for tubulin [10,18]. However in cells, (+)-discoder-
molide was less cytotoxic than Taxol [18,19]. Recently, we
have reported that Taxol and (+)-discodermolide represent
a synergistic drug combination in human carcinoma cell
lines, and as such may comprise a useful chemotherapeutic
drug combination [19].
Although (+)-discodermolide holds promise as a cancer
chemotherapeutic agent, the scarcity of the natural prod-
uct (0.002% w/w from frozen sponge) had precluded fur-
ther development of this agent as a drug. It is therefore
not surprising that discodermolide has attracted consider-
able interest from the synthetic community resulting in
seven total syntheses [20^26]. This includes our ¢rst-gen-
eration ent-discodermolide synthesis followed by a second-
generation gram-scale synthesis of the natural isomer (+)-
discodermolide [21,25]. In addition, two groups have re-
ported the synthesis of analogs, laying the groundwork for
a more detailed SAR study [27,28]. SAR studies have been
performed with Taxol [29], the epothilones [30,31], and
eleutherobin [32], but to date no SAR analyses examining
microtubule stability and cellular e¡ects have been re-
ported for (+)-discodermolide. The present study com-
pares the activity of discodermolide with four new analogs
(Fig. 1), both in vitro and in cells, thereby providing im-
portant new information on the structural requirements
responsible for the unique nucleation activity and potency
of (+)-discodermolide.
2. Results
2.1. Synthesis of discodermolide analogs using a triply
convergent approach
From the synthetic perspective, the polyproprionate
structure of (+)-discodermolide revealed Z-ole¢nic link-
ages at C8^C9, C13^C14 and C21^C22, in addition to
the carbamate and N-lactone moieties (Fig. 1). The C13^
C14 trisubstituted Z-ole¢n in particular represented a sig-
ni¢cant synthetic challenge. Indeed, installation of this
structural unit proved troublesome for all previous syn-
thetic approaches. We reasoned that modi¢cation of the
discodermolide structure via deletion of the C14 methyl
group, generating a Z-disubstituted ole¢n instead of the
Z-trisubstituted ole¢n at C13^C14, would not only simpli-
fy the structure of the natural product, but also prospec-
tive synthetic strategies while retaining the biological ac-
tivity. Support for the latter conjecture derives from the
work of Hung et al., who reported that deletion of the C16
methyl group resulted in little or no loss of activity [27].
However, the group observed that changes in the C17^C20
region of the discodermolide backbone resulted in almost
complete loss of activity [27]. Our focus thus turned to
modi¢cation of the C1^C14 region of discodermolide
with particular interest in the C14-normethyl analog (2).
Ideally suited for this synthetic venture was our triply
convergent synthetic approach to (+)-discodermolide
[25,33]. In addition, a late stage Wittig ole¢nation to in-
stall a variety of C1^C8 structure motifs would permit
exploration, for the ¢rst time, of the SARs in this region.
The construction of other potentially important C1^C14
analogs also would be feasible due to the availability of
signi¢cant quantities of several advanced intermediates.
For example, in the late stage Wittig ole¢nation leading
to discodermolide (Scheme 1), we observed high selectivity
(24:1 Z/E) favoring the Z-ole¢n 7 (69% yield); 7 was
subsequently carried on to (+)-discodermolide (86%, three
steps). To probe the importance of the ole¢n geometry at
C8^C9, the minor E-ole¢nic isomer also was subjected to
the same end game strategy. Oxidative removal of the
paramethoxybenzyl (PMB) group with DDQ a¡orded
the corresponding alcohol (52% yield), which was then
subjected to the Kocovsky protocol to install the carba-
mate [34]. Global desilylation furnished the C(8, 9) E ana-
log (3)-4 in good yield (95%, two steps).
Another minor byproduct resulting from our gram-scale
synthesis arose during the ¢nal global deprotection (i.e.
7C(+)-discodermolide). Although the acidic conditions
(3 N HCl, MeOH) led to the natural product reliably
and in good yield (93%), the minor byproduct available
due to the large scale synthesis proved to be the K,L-un-
saturated N-lactone (+)-1, obtained after puri¢cation by
high performance liquid chromatography and recrystalli-
zation (CH3CN); the structure was secured by single crys-
tal X-ray analysis.
To probe further the substituents necessary for activity
along the C1^C8 backbone, we sought several deletion
analogs. Having developed a reliable route to terminal
ole¢n (+)-8 (Scheme 2) during the optimization of (3)-6
[33], synthesis of an analog deoxygenated at C7 appeared
feasible. Hydroboration of the terminal ole¢n using the
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Evans protocol [35] provided alcohol (3)-9 (70%); Par-
ikh^Doering oxidation [36] then furnished aldehyde (3)-
10 (80%). Although Wittig ole¢nation (Scheme 1) resulted
in a modest yield (8%) of the Z-ole¢n 11, we were able to
complete the synthesis of the C7 deoxygenated analog.
Towards this end, removal of the PMB group (DDQ,
H2O, 99%) followed by installation of the carbamate via
the Kocovsky protocol furnished the carbamate. Surpris-
ingly, treatment of the carbamate, as in our large scale
synthesis of (+)-discodermolide (e.g. 3 N HCl, MeOH),
led to (+)-3, the K,L-unsaturated N-lactone as the major
product (56%, two steps). Presumably the dehydration oc-
curs in this case as a result of subtle conformational
changes induced by deoxygenation at C7.
Our attention next turned to construction of the C14-
normethyl analog of discodermolide (+)-2 possessing a
C8^C9 Z-ole¢n. As in our large scale discodermolide syn-
theses, we envisioned a Wittig reaction to introduce the Z-
ole¢n linkage. In the earlier discodermolide syntheses, sev-
eral groups [21,22] observed that the vigorous conditions
required to generate the phosphonium salt 5 (Scheme 1)
resulted in an undesired intramolecular cyclization involv-
ing the C13^C14 trisubstituted ole¢n. Generation of the
Wittig salt at high pressure circumvented this problem
[33]. We reasoned that replacement of the trisubstituted
ole¢n with a cis-disubstituted ole¢n would in all likelihood
negate the need for high pressure and thereby signi¢cantly
simplify the overall synthetic strategy.
Our point of departure for the C14-normethyl analog
(+)-2 entailed a Stork^Zhao ole¢nation [37] of aldehyde
(3)-12 [33] (Scheme 3) to furnish vinyl iodide (+)-13 (13:1
Z/E ; 73%), which upon Negishi cross-coupling [38] with
Fig. 1. Chemical structures of Taxol, the epothilones, eleutherobin, (+)-discodermolide, and discodermolide analogs 1^4.
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our previously prepared iodide (+)-14 [33] furnished ole¢n
(+)-15. To facilitate the required discrimination of the C19
hydroxyl, we introduced a protecting group interchange.
Speci¢cally, the PMB group in (+)-15 was removed che-
moselectively (DDQ, H2O, 80%) and replaced with a trityl
moiety (tritylchloride, DMAP, pyr. 81%) to provide (+)-
16.
Installation of the C21^C24 terminal Z-diene (Scheme
3) began with reductive opening of acetal (+)-16 with DI-
BAL [39] followed by Dess^Martin oxidation [40]. The
resulting aldehyde was then subjected to the Yamamoto
diene synthesis [41] to furnish 17 (10:1 Z/E) in 63% yield
(two steps). Removal of the minor E-diene isomer was
accomplished at a later stage of the synthesis as previously
achieved in our discodermolide synthesis [33]. The trityl
group was next removed [42] (chlorocatecholborane,
80%), followed by conversion of the resulting alcohol to
the iodide (Ph3P, I2, PhH/Et2O) [43,44] to set the stage for
generation of the Wittig salt. Intermolecular displacement
of the iodide via molten triphenylphosphine (Hunig’s base,
85‡C) furnished the phosphonium salt 18 in high yield
(95%, two steps), without involvement of the C13^C14
ole¢n. Thus, removal of the C14 methyl group from dis-
codermolide signi¢cantly simpli¢es the generation of the
requisite phosphonium salt and thereby the overall syn-
thetic sequence.
Wittig coupling of the ylide 18 (Scheme 1) with alde-
hyde (3)-6 [33] proceeded in 40% yield (7:1 Z/E) along
with 35% recovery of the phosphonium salt which could
be reused. Oxidative removal of the PMB moiety in 19
(DDQ, H2O, 97%), installation of the carbamate via the
Kocovsky protocol, and global deprotection (3 N HCl,
MeOH; 89%) then furnished the C14-normethyl analog
of discodermolide (+)-2.
2.2. Minor structural modi¢cations of (+)-discodermolide
result in a decrease in tubulin nucleation
The activities of Taxol, (+)-discodermolide, and the
structural analogs were determined in an in vitro tubulin
polymerization assay that measures changes in absorbance
that correlate with the extent of microtubule polymeriza-
tion. Microtubule polymerization involves both nucleation
(initiation) and elongation steps. The initial rates of poly-
merization re£ect the nucleation process [45]. Taxol, (+)-
Scheme 1. Syntheses of (+)-discodermolide and analogs 1^4.
Scheme 2. Synthesis of modi¢ed C1^C8 coupling partner (3)-10. Scheme 3. Synthesis of C14-normethyl phosphonium salt 18.
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discodermolide, and the four analogs (Fig. 1) all induced
tubulin assembly in the absence of GTP that is normally
required for microtubule assembly (Fig. 2). The microtu-
bules formed in the presence of Taxol, (+)-discodermolide,
and the analogs were all stable against calcium-induced
depolymerization (data not shown).
Two distinct observations were made. First, the extents
of polymerization for (+)-discodermolide, analogs 1 and 2,
and Taxol were essentially the same after 100 min (Fig. 2,
curves 1^4). Analogs 3 and 4 demonstrated reduced poly-
merization, attaining approximately 50% of the level of
polymerization observed with (+)-discodermolide (Fig. 2,
curves 5 and 6). The proportion of polymerized tubulin
for each compound also was determined by removing 200
Wl aliquots at the end of the assay, centrifuging at
100 000Ug for 30 min, and measuring the protein content
in the supernatant. By this method, the level of polymer-
ization induced by (+)-discodermolide and analogs 1 and 2
was comparable, whereas analogs 3 and 4 had approxi-
mately 50% more protein in the supernatant and hence less
polymer in the precipitate (data not shown). Second, the
initial slopes (0^5 min) are presented in the inset in Fig. 2.
The slope for (+)-discodermolide (curve 1) was assigned a
value of 1.0 to which the slopes for the other compounds
were compared. The structural analogs (curves 3^6) gave
values of 0.26, 0.39, 0.08, and 0.14, respectively; Taxol
had a value of 0.28 (curve 2). These data re£ect the potent
nucleating activity of (+)-discodermolide, and its extreme
sensitivity to small modi¢cations in the (+)-discodermolide
structure.
2.3. Electron microscopy (EM) reveals di¡erences in the
lengths of microtubules formed in the presence of
(+)-discodermolide compared to the analogs
The microtubule protein (MTP) from each in vitro as-
say was examined by EM to con¢rm that normal micro-
tubules were formed in the presence of the compounds. In
all cases, except for the dimethyl sulfoxide (DMSO) con-
trol, microtubules were observed (data not shown). As has
been noted previously [18], (+)-discodermolide produced
much shorter microtubules than those formed in the pres-
ence of GTP or Taxol, emphasizing the major e¡ect that
(+)-discodermolide has on microtubule nucleation (Fig.
3a^d). Most interesting was the observation that small
changes in the (+)-discodermolide structure, such as in
analog 1, resulted in a signi¢cant loss of the enhancement
of tubulin nucleation (Fig. 3e,f). The microtubules as-
sembled in the presence of (+)-discodermolide were ap-
proximately 5-fold, 12-fold, and 4-fold shorter than those
formed by analogs 1 and 2, by analogs 3 and 4, and by
Taxol, respectively (Table 1).
2.4. The drug binding competition assay demonstrates that
(+)-discodermolide and the analogs are competitive
inhibitors of [3H]Taxol binding
In order to determine the ability of the discodermolide
analogs to inhibit the binding of Taxol to preformed mi-
crotubules, a drug binding competition assay was per-
formed using [3H]Taxol and puri¢ed tubulin. It was found
Fig. 2. In vitro activities of Taxol, (+)-discodermolide, and the analogs using a tubulin polymerization assay. MTP was diluted to 1 mg/ml in MES bu¡-
er containing 3 M glycerol and the compounds (10 WM) to be evaluated were then added in 1 min intervals (between the arrows) to the MTP incubat-
ing at 37‡C. The change in absorbance was followed at 350 nm for 100 min. 1, (+)-discodermolide; 2, Taxol ; 3, analog 1 ; 4, analog 2 ; 5, analog 3 ; 6,
analog 4 ; 7, control (DMSO). Inset, initial slope (0^5 min) of Taxol, (+)-discodermolide, and analogs 1^4.
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that each of the drugs was a competitive inhibitor of the
binding of [3H]Taxol to the preformed microtubules. At
1 WM, Taxol, (+)-discodermolide, and analogs 1^3 exhib-
ited very similar inhibition, whereas analog 4 was essen-
tially inactive in displacing [3H]Taxol binding (Fig. 4).
Taxol and (+)-discodermolide, at 10 WM, inhibited the
binding of [3H]Taxol by approximately 45%. The disco-
dermolide analogs demonstrated between 5 and 40% inhi-
bition. The di¡erences between the drugs were apparent at
100 WM with (+)-discodermolide displaying almost 95%
inhibition and Taxol with 80% inhibition. Analog 1 exhib-
ited greater than 90% inhibition. Discodermolide analogs
2^4 demonstrated a range of between 45 and 65% inhibi-
tion. The relative binding a⁄nities of the molecules, the
EC50 and EC75 (inset in Fig. 4), were calculated from the
plot of competitive inhibition of [3H]Taxol binding (Fig. 4).
2.5. (+)-Discodermolide and the analogs prove active in
human A549 and SKOV3 carcinoma cell lines
(+)-Discodermolide and the analogs all inhibited the
proliferation of A549 cells, but to di¡erent extents. Taxol
and analog 1 shared similar IC50 values, followed by (+)-
discodermolide (Table 2). Analog 2, which was as active in
vitro as the above compounds, was approximately 2-fold
less cytotoxic than (+)-discodermolide. Although analogs
3 and 4 both shared similar in vitro activity, analog 3 had
an approximately 3-fold decrease in cytotoxicity while
analog 4 had a 128-fold decrease compared to (+)-disco-
dermolide. Similar results were obtained with SKOV3
cells, although (+)-discodermolide was approximately
8-fold less active in this cell line compared to A549 cells
Fig. 3. Electron micrographs of samples from the tubulin polymerization assay demonstrated di¡erences in microtubule length. Aliquots (50 Wl) were
taken from the cuvettes at the completion of the in vitro assay (100 min) and processed for EM analysis. (a,b) Taxol, (c,d) (+)-discodermolide, and
(e,f) analog 1. (a,c,e) U5000 magni¢cation; (b,d,f) U20 000 magni¢cation.
Table 1
A comparison of microtubule lengths after assembly with Taxol, disco-
dermolide, and analogs
Compound Average polymer length (Wm)
Taxol 3.3 þ 1.2a
Discodermolide 0.78 þ 0.3
1 5.1 þ 2.2
2 3.0 þ 1.0
3 9.3 þ 4.0
4 9.8 þ 4.9
aMean þ S.E.M.
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(Table 2). Taxol and analog 1 had comparable IC50 val-
ues, while discodermolide, analog 2, and analog 3 were
less cytotoxic. As seen in A549 cells, analog 4 displayed
the greatest decrease in cytotoxicity.
2.6. A549 cells arrest in mitosis and display microtubule
bundles in the presence of (+)-discodermolide and the
analogs
Under control conditions, A549 cells exhibited a normal
cell cycle pro¢le, microtubule cytoskeleton, and DNA
staining (Figs. 5a and 6a). Analysis by £ow cytometry
indicated that A549 cells are blocked in the G2/M phase
of the cell cycle after exposure to a cytotoxic concentration
(25 nM) of (+)-discodermolide (Fig. 5b). An increase in
the hypodiploid population of cells also was observed,
most likely indicating apoptosis. Microtubule bundles
and condensed nuclear DNA appeared at this concentra-
Fig. 4. (+)-Discodermolide and the analogs competitively inhibit the binding of [3H]Taxol to microtubules. Preformed microtubules were incubated with
100 nM [3H]Taxol and competing drugs at 37‡C for 30 min. Microtubules were collected by ultracentrifugation and the radioactivity was determined
using a liquid scintillation counter. 1, Taxol; 2, (+)-discodermolide ; 3, analog 1 ; 4, analog 2 ; 5, analog 3 ; 6, analog 4. Inset, EC50 and EC75 values for
Taxol, (+)-discodermolide, and analogs 1^4.
Table 2
Cytotoxicity of Taxol, discodermolide, and its analogs in the human
A549 and SKOV3 cell lines
Compound IC50 (nM)a
A549 SKOV3
Taxol 1.4 þ 0.5b 3.3 þ 0.5
Discodermolide 3.8 þ 0.6 31.3 þ 6.8
1 1.8 þ 0.1 6.1 þ 3.7
2 7.8 þ 3.3 22.0 þ 10.6
3 11.4 þ 3.2 31.3 þ 16.5
4 485.0 þ 6.4 353.0 þ 0.8
aIC50, drug concentration that inhibits cell division by 50% after 72 h.
bMean þ S.E.M.
Fig. 5. (+)-Discodermolide and the analogs all induce mitotic arrest in
A549 cells. Cells were incubated with di¡erent compounds for 24 h,
¢xed, stained with propidium iodide, and analyzed by £ow cytometry.
(a) Control (DMSO), (b) (+)-discodermolide (25 nM), (c) analog 1 (10
nM), (d) analog 2 (25 nM), (e) analog 3 (50 nM), and (f) analog 4 (10
WM).
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tion as shown by immuno£uorescence (Fig. 6b). This e¡ect
also was seen at concentrations above 25 nM, but not at
concentrations below 12 nM (data not shown). Bundle
formations observed with (+)-discodermolide were dis-
tinctly di¡erent from those noted with Taxol. In the pres-
ence of (+)-discodermolide, microtubule bundles were seen
at the periphery of the cells, in contrast to Taxol, where
the bundles were present throughout the cells (data not
shown). At di¡erent cytotoxic concentrations, the disco-
dermolide analogs caused arrest in the G2/M phase of the
cell cycle and induced microtubule bundling and DNA
condensation (Figs. 5c^f and 6c^f).
2.7. (+)-Discodermolide and Taxol ¢t within the same
binding pocket in the L-tubulin model
Both the crystal and recent solution structures of (+)-
discodermolide [46] demonstrated that the molecule ar-
ranges the C1^C19 region into a U-shaped conformation
bringing the N-lactone and the C19 side chain in close
proximity. When overlaid with Taxol, the backbone of
(+)-discodermolide mimics the northern portion of the
taxane ring. The N-lactone and the C19 side chain of
(+)-discodermolide correspond to the C13 and C2 side
chains of Taxol. However, the position of the N-lactone
and the C19 side chain with respect to the side chains of
Taxol cannot be determined at this point (Fig. 7a,b). Since
the crystal/solution structure of the (+)-discodermolide
molecule can ¢t into the Taxol binding pocket within L-
tubulin in either of two orientations, two models have
been proposed (Fig. 7c,d).
In model I (Fig. 7c), the C19 side chain of (+)-discoder-
molide, like the C2 benzoyl group of Taxol, binds in a
pocket formed by His227 and Asp224 and both side
chains are approximately 2^3 Aî away from these amino
acids. A comparison of the structures of Taxol and Tax-
otere, both used for the treatment of human carcinomas
[1], shows a replacement at the C10 position (hydroxyl
Fig. 6. Microtubule bundle formation is observed in the presence of cytotoxic concentrations of (+)-discodermolide and the analogs. For immuno£uo-
rescence studies, A549 cells were grown on coverslips and treated with the di¡erent compounds for 24 h. Cells were then permeabilized, ¢xed, and
stained with K-tubulin primary antibody, Cy3 secondary antibody and Hoechst DNA stain. (a) Control (DMSO), (b) (+)-discodermolide (25 nM),
(c) analog 1 (10 nM), (d) analog 2 (25 nM), (e) analog 3 (50 nM), and (f) analog 4 (10 WM).
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group) and the C3P position on the C13 side chain (tertiary
butyl group) in the Taxotere structure (Fig. 1). If Taxol is
replaced by Taxotere, modeling studies revealed a much
better ¢t between the N-lactone of (+)-discodermolide and
the C13 side chain of Taxotere. The C4 methyl group of
the N-lactone is approximately 1 Aî away from His227,
while the tertiary butyl group is approximately 2.5 Aî in
distance from His227. The C11 hydroxyl group of (+)-
discodermolide matches with the C10 acetyl group of Tax-
ol and both groups are approximately 2.5 Aî from Gly368.
The ¢nal contact with Thr274 is made between C24 of (+)-
discodermolide and the C7 hydroxyl group of Taxol, both
approximately 2.8 Aî from Thr274.
In model II (Fig. 7d), the N-lactone ¢ts into the binding
pocket formed by His227 and Asp224, in a similar manner
to the C2 benzoyl group of Taxol. The C4 methyl group of
the N-lactone is approximately 1 Aî from His227 and 3 Aî
from Asp224. The C19 side chain of (+)-discodermolide is
found near His227 (approximately 5 Aî away), similar to
the C3P tertiary butyl group of Taxotere. The C7 hydroxyl
group of Taxol matches with the C10 methyl group of (+)-
discodermolide, making contact with Thr274. The C10
methyl group is approximately 2.5 Aî from the hydroxyl
group of Thr274. The Gly368 contact is made between the
C12 methyl group (4 Aî ) and C24 (1.3 Aî ) of (+)-discoder-
molide, in a similar manner to that of the C10 acetyl
group of Taxol.
The four discodermolide analogs also were modeled in
place of (+)-discodermolide in the L-tubulin structure
(data not shown). In model I, analogs 1, 2, and 3 do
not lose any important contacts with L-tubulin since the
positions on the molecule that have been modi¢ed are not
in contact with what appear to be important residues re-
sponsible for drug binding. In analog 1, the C4 methyl
group is in contact with His227 of L-tubulin while the
C3 hydroxyl group that was removed did not make any
signi¢cant contacts. The C14 methyl group of analog 2
and the C7 hydroxyl group of analog 3 both are present
in an open area within the drug binding pocket. Analog 3
may be slightly less cytotoxic due to the additive e¡ect of
removing both the C3 and C7 hydroxyl groups. A com-
parison of (+)-discodermolide with analog 4, which has
the altered ole¢n geometry at C8, not surprisingly demon-
strated a dramatic change in the overall conformation. In
particular, the N-lactone of analog 4 would lose binding to
His227 when placed into the L-tubulin model and would
no longer mimic the tertiary butyl group of Taxotere. In-
stead, the N-lactone is shifted, losing contact with His227
and making new contacts with L-tubulin, possibly at
Leu273. New interactions may explain why this analog,
although less cytotoxic than analogs 1^3, retains some
activity. In model II, analogs 1 and 2 again do not lose
the necessary contacts within the drug binding pocket. In
contrast, analog 3 would lose a speci¢c contact with
Arg276 that appears to be important for binding and ac-
tivity, and analog 4 would lose all contacts, including
those with His227 and Asp224. Moreover, the N-lactone
of analog 4 would now point out of the binding pocket
Fig. 7. (+)-Discodermolide mimics Taxol and binds into a pocket formed by Gly368, Thr274, His227 and Asp224 in L-tubulin. (a) Model I : the folded
U-shaped backbone of (+)-discodermolide matches with the taxane ring of Taxol and the C19 side chain of (+)-discodermolide mimics the C2 side
chain of Taxol, while the N-lactone of (+)-discodermolide emulates the C13 side chain of Taxol (pink: Taxol; green: (+)-discodermolide). (b) Model II:
the N-lactone of (+)-discodermolide matches with the C2 side chain of Taxol and the C19 side chain of (+)-discodermolide mimics the C13 side chain of
Taxol. (c) Model I : (+)-discodermolide, in the ¢rst orientation as seen in (a), ¢ts into the Taxol binding pocket formed by Gly368, Thr274, His227, and
Asp224 of L-tubulin (pink: Taxotere; green: (+)-discodermolide; L-tubulin amino acids highlighted in purple). (d) Model II: (+)-discodermolide, in the
second orientation as seen in (b), also ¢ts into the Taxol binding pocket within L-tubulin.
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towards the lumen of the microtubule structure. Since
analog 3 does not demonstrate a signi¢cant decrease in
cytotoxicity and analog 4 retains activity in the high nM
range, model II is not supported. Therefore, we favor
model I as the orientation of (+)-discodermolide within
the L-tubulin structure. The availability of additional syn-
thetic analogs should increase our knowledge of the inter-
action between (+)-discodermolide and microtubules.
3. Discussion
In this report, we have compared the activity of (+)-
discodermolide with four structural analogs. Our results
suggest a common pharmacophore model for Taxol and
(+)-discodermolide. The in vitro studies demonstrated that
(+)-discodermolide and the structural analogs induced tu-
bulin assembly in the absence of GTP and that the micro-
tubules formed were stable under depolymerizing condi-
tions. The initial rate of tubulin polymerization in the
presence of (+)-discodermolide was dramatically di¡erent
compared to the analogs. Even a single change to the (+)-
discodermolide structure reduced the potent nucleating ac-
tivity of the analogs, presumably due to a loss of a speci¢c
contact between the analogs and L-tubulin that must be
necessary for enhanced initiation of tubulin polymeriza-
tion. It has been noted that Taxol does not possess the
same ability to hypernucleate tubulin assembly as (+)-dis-
codermolide [10], and that (+)-discodermolide produced
shorter microtubules than Taxol [18]. EM revealed that
the microtubules formed in the presence of (+)-discoder-
molide were signi¢cantly shorter than those produced by
the analogs and by Taxol. In addition, (+)-discodermolide
and the analogs inhibited the binding of [3H]Taxol to mi-
crotubules, but to di¡erent extents. (+)-Discodermolide
and the analogs also were cytotoxic to human A549 lung
and SKOV3 ovarian carcinoma cells. In both cell lines,
analog 4 displayed the most dramatic decrease in cytotox-
icity. Although analog 4 is only 50% less active in vitro, in
A549 and SKOV3 cells analog 4 exhibited a much more
signi¢cant decrease in cytotoxicity compared to the other
analogs. This e¡ect could be due to a decrease in accessi-
bility to the L-tubulin binding sites in cells, compared to in
vitro conditions with puri¢ed tubulin. The results from the
three di¡erent assays, the in vitro tubulin assembly assay,
the [3H]Taxol binding competition assay, and the cytotox-
icity studies, indicated that Taxol, (+)-discodermolide, and
analog 1 are the most active compounds whereas analogs
3 and 4, especially analog 4, are the least active. The
results obtained from calculating the relative binding af-
¢nities have suggested that the interaction of the drug with
the microtubule is not always correlative with cytotoxicity.
It should be noted that the in vitro assembly assay pro-
vides information such as the unique nucleating activity of
(+)-discodermolide that is not observed in any of the other
assays.
The (+)-discodermolide X-ray/solution structure was
modeled with Taxol and the overall conformation was
found to be similar in both orientations (models I and
II) (Fig. 7a,b). The backbone of (+)-discodermolide, as
displayed in the crystal/solution conformation, overlaid
the northern portion of the taxane ring. Our previous
photoa⁄nity labeling studies and molecular modeling
work have suggested that Taxol binds into a pocket
formed by Gly368, Thr274, His227, and Asp224 in L-tu-
bulin [15,47]. This information allowed us to suggest that
like Taxol, (+)-discodermolide ¢ts into this L-tubulin bind-
ing cavity and thereby a¡ects the M-loop of L-tubulin and
stabilizes the interactions between adjacent proto¢laments
[15,48]. This is consistent with the observations that (+)-
discodermolide possesses a similar mechanism of action as
Taxol and that (+)-discodermolide and Taxol compete for
a binding site in L-tubulin [11]. Using this model, (+)-dis-
codermolide was found to ¢t into the Taxol binding pock-
et in either of two binding modes (models I and II) (Fig.
7c,d).
The modeling work performed with (+)-discodermolide
has shed further light on a common pharmacophore for
Taxol, the epothilones, eleutherobin, and (+)-discodermo-
lide. Two elements appear to be required for microtubule-
stabilizing activities : a core ring structure similar to the
taxane ring of Taxol and a side chain comparable to the
C2 benzoyl group of Taxol. The C13 side chain is not an
absolute requirement for Taxol-like activity, since 2-m-azi-
do baccatin III has activity that is dependent on the sub-
stituent at the 2-meta position [15]. The macrolide ring of
the epothilones, the core ring system of eleutherobin, and
the U-shaped backbone of (+)-discodermolide all mimic
the taxane ring of Taxol. The thiazole side chain of the
epothilones, the C8 methylurocanic acid side chain of eleu-
therobin, and the C19 side chain of (+)-discodermolide
match with the C2 benzoyl group of Taxol. The core
structure of these compounds binds in a pocket formed
by Gly368, Thr274, His227 and Asp224 in L-tubulin and
their side chains ¢t into a pocket formed by His227 and
Asp224 [15].
There are still unresolved issues relating to the activity
of (+)-discodermolide. For example, it is not obvious why
(+)-discodermolide, compared to the analogs and Taxol, is
extremely competent at initiating tubulin polymerization
or how this may a¡ect the chemotherapeutic activity of
the drug. Also, a lack of cross-resistance to (+)-discoder-
molide was found in the A549-T12 Taxol-resistant cell
line, although the cells were cross-resistant to the epothi-
lones. In addition, (+)-discodermolide was unable to sub-
stitute for Taxol in A549-T12 cells that require low con-
centrations of Taxol for normal growth [19]. In contrast,
the epothilones were able to support the growth of A549-
T12 cells. This cell line does not have a mutation in class I
L-tubulin (L.A. Martello, unpublished observation). Fur-
thermore, epothilone-resistant cells with class I L-tubulin
mutations displayed no cross-resistance to (+)-discoder-
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molide (P. Giannakakou, personal communication). These
results suggest that there are distinct di¡erences between
the interaction of Taxol, the epothilones, and (+)-disco-
dermolide with microtubules that may indicate overlap-
ping but not identical binding sites. In comparison to
Taxol, (+)-discodermolide may be forming additional or
discrete contacts within the L-tubulin structure. It is pos-
sible that (+)-discodermolide also may have additional
targets within cells that allow it to remain cytotoxic in
drug-resistant cell lines that may or may not have L-tubu-
lin mutations.
4. Signi¢cance
Discodermolide analogs (1^4) were synthesized via a
highly e⁄cient, triply convergent approach to (+)-disco-
dermolide and evaluated both in vitro and in human car-
cinoma cell lines. The analogs were devised not only to
simplify the structure of (+)-discodermolide but also the
required synthetic strategy, while retaining cytotoxic activ-
ity. The SAR studies demonstrated that small changes to
the (+)-discodermolide structure resulted in a dramatic
decrease in the initiation of tubulin polymerization. Spe-
ci¢c modi¢cations made to analogs 3 and 4 also caused a
decrease in total tubulin polymerization. In addition, a
change in the ole¢n geometry at C8 in analog 4 produced
a signi¢cant decrease in cytotoxicity. Molecular modeling
studies using the X-ray/solution structure of (+)-discoder-
molide revealed that the molecule folds into a U-shaped
conformation. Two potential binding models were possible
when the X-ray/solution structure of (+)-discodermolide
was docked into the Taxol binding pocket in L-tubulin.
Model I, in which the C19 side chain of (+)-discodermo-
lide matches with the C2 benzoyl group of Taxol and the
N-lactone of (+)-discodermolide ¢ts with the C13 side
chain of Taxol, is most consistent with the results of
the SAR studies. Finally, this report presents important
information on the structural requirements of (+)-disco-
dermolide that confer unique activity and potency. Our
future goals are to explore further the similarities and
di¡erences between Taxol and (+)-discodermolide in order
to exploit this knowledge for both the design of new
cancer chemotherapeutic drugs and improved treatment
regimens.
5. Materials and methods
5.1. Materials
All drugs were dissolved in sterile DMSO and stored at 320‡C.
MTP was puri¢ed by two cycles of temperature-dependent assem-
bly^disassembly from calf brain and stored in liquid nitrogen [49].
The concentration of tubulin in the MTP preparation was ap-
proximately 85%.
5.2. Cell culture
The A549 lung carcinoma cell line was maintained as described
previously [50]. The SKOV3 ovarian carcinoma cell line was ob-
tained from Dr. V. Ling and was maintained as described pre-
viously [32].
5.3. In vitro tubulin polymerization assay
Microtubule polymerization was evaluated by recording the
change in turbidity of MTP at 350 nm for 100 min in a spectro-
photometer (UVIKON, Research Instruments Int., San Diego,
CA, USA) [51]. Puri¢ed MTP was diluted in assembly bu¡er
containing 0.1 M MES, 1 mM EGTA, 0.5 mM MgCl2, and
3 M glycerol (pH 6.6) to a ¢nal concentration of 1 mg/ml. All
compounds were evaluated at a concentration of 10 WM at 37‡C
in the absence of GTP. The changes in absorption that occurred
during the ¢rst 5 min were used to plot initial slopes from the
linear portion of each curve in order to compare the initial ac-
tivity of each compound.
5.4. EM
Aliquots (50 Wl) were taken from the in vitro polymerization
assay at the end of the reaction and placed onto 300-mesh car-
bon-coated, Formavar-treated copper grids. Samples were then
stained with 20 Wl of 2% uranyl acetate and viewed with a
JEOL model 100CX electron microscope. To determine the
lengths of the microtubules, electron micrograph negatives were
scanned and then analyzed using IP Lab software. Measurements
were performed on negatives at U10 000 and U5000, with a
minimum of 50 microtubules measured for each compound.
5.5. Drug binding competition assay
The assay was performed using methods described previously
[8,15]. MTP (0.4 mg/ml) was incubated at 37‡C with 1 mM GTP
and 7.5 nM Taxol for 20 min to induce the assembly of micro-
tubules. One hundred nM [3H]Taxol (speci¢c activity: 19.3
Ci/mmol) and the indicated concentration of the competing agent
were added simultaneously to the preformed microtubules. The
mixtures were further incubated at 37‡C for 30 min to allow
binding of [3H]Taxol. Microtubules were collected by ultracentri-
fugation (100 000Ug, 1 h, 30‡C) and the radioactivity measured
using a liquid scintillation counter. The inhibition of binding of
[3H]Taxol to microtubules was expressed as a percentage com-
pared to the control (100%). The determination of the relative
binding a⁄nities using the percentage of competitive inhibition of
[3H]Taxol binding was obtained through linear regression analy-
sis. The e¡ective concentrations that inhibit 50% (EC50) and 75%
(EC75) of [3H]Taxol binding were determined.
5.6. Cytotoxicity assays
A549 cells were seeded in triplicate at a density of 1U104 cells/
ml in 6-well plates and allowed to attach for 24 h. After incuba-
tion with various drug concentrations for 72 h, adherent cells
were trypsinized and counted (Coulter Counter model Z1; Coult-
er Corp., Miami, FL, USA), and the IC50 was determined.
SKOV3 cells were seeded at a density of 2U104 cells/ml and
the above procedure followed.
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5.7. Flow cytometry
A549 cells were prepared for £ow cytometry as described pre-
viously except that drug treatment was for 24 h [19].
5.8. Immuno£uorescence
A549 cells were prepared for immuno£uorescence as described
previously [19]. In addition, cells were stained with Hoechst so-
lution (Sigma; 1:2.5 dilution) for 15 min after the secondary
antibody wash. Slides were analyzed using a Zeiss Axiophot
microscope (rhodamine and DAPI ¢lters) at U100 magni¢cation.
5.9. Molecular modeling
Molecular modeling studies were performed using the Insight
II software (Molecular Simulations Inc.). The K,L-tubulin struc-
ture was taken from Nogales et al. (PDB code: 1TUB) [52]. The
coordinates for the Taxol X-ray structure were developed by
Mastropaolo et al. [53] and the Taxotere X-ray structure coordi-
nates were acquired from Gueritte-Voegelein et al. [54]. The co-
ordinates for (+)-discodermolide, obtained from Gunasekera et
al., required sign inversion to conform to the correct absolute
stereochemistry [55].
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